Why the study?
Does long-term chemotherapy as a prophylactic adjunct to primary surgical resection improve cure rates in patients with operable breast cancer?
Does long-term chemotherapy as a prophylactic adjunct to primary surgical resection improve cure rates in patients with operable breast cancer?
Discusses the rationale for long-term prophylactic chemotherapy in operable breast cancer to address micrometastases.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mary E. Costanza (1975) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: